Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.37 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6418044 | 0.98 | NAMPT (0.47) | NAMPTPTGS1PTGS2APOBEC3AAPOBEC3G | |
| SCHEMBL17169816 | 0.84 | NAMPT (0.44) | NAMPTPTGS1PTGS2CBLBMEN1 | |
| SCHEMBL21500646 | 0.84 | NAMPT (0.44) | NAMPTPTGS1PTGS2CBLBMEN1 | |
| Hydrochloric Acid SCHEMBL31250002 | 0.82 | NAMPT (0.43) | NAMPTCBLBMEN1CYP1A2KMT2A | |
| SCHEMBL24998437 | 0.80 | NAMPT (0.44) | NAMPTKDM4ECBLBMEN1CYP1A2 | |
| SCHEMBL15718343 | 0.80 | NAMPT (0.50) | NAMPTPTGS1PTGS2KDM4ECBLB | |
| Trifluoroacetic Acid SCHEMBL30258754 | 0.78 | NAMPT (0.41) | NAMPTPTGS1PTGS2CBLBKMT2A | |
| SCHEMBL17324577 | 0.76 | NAMPT (0.39) | NAMPTCBLBMEN1CYP1A2KMT2A | |
| SCHEMBL6410488 | 0.76 | KDM4E (0.53) | NAMPTKDM4ECBLBCYP1A2ALDH1A1 | |
| SCHEMBL31149258 | 0.75 | NAMPT (0.41) | NAMPTPTGS1PTGS2APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098667-A1 | USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4695252-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213659-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | NAMPT 1846/4885PTGS1 3150/4885PTGS2 3226/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | NAMPT 2282/4885PTGS1 1149/4885PTGS2 1613/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | NAMPT 3175/4885PTGS1 4502/4885PTGS2 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.